Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  dacarbazine
Find trials that include:  Any drugs shown
Trial Status:  Active
Results 1-25 of 37 for your search:
Start Over
Standard Palliative Care Versus Standard Palliative Care Plus Polychemotherapy in Metastasized Malignant Melanoma
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: ADO-MM-PAL8, NCT00226473
Optimization of the Primary Therapy for Patients With Hodgkin's Disease and Evaluation of PET
Phase: Phase IV
Type: Treatment
Status: Active
Age: 16 to 75
Sponsor: Other
Protocol IDs: CGC05MK1002, NCT00188149
Combination Chemotherapy in Treating Young Patients With Hodgkin's Lymphoma
Phase: Phase III
Type: Diagnostic, Treatment
Status: Active
Age: 17 and under
Sponsor: Other
Protocol IDs: CDR0000531687, EURONET-PHL-C1, EU-20703, EUDRACT-2006-000995-33, CCLG-HD-2007-10, NCT00433459
HD16 for Early Stage Hodgkin Lymphoma
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: HD16, NCT00736320
Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 101.321-13/07, EudraCT Nr. 2008-001686-28, NCT00779714
Study Evaluating the Effect of R-mabHDI in Lymphocytic Predominant Hodgkin's Lymphoma
Phase: Phase III
Type: Treatment
Status: Approved-not yet active
Age: 16 to 65
Sponsor: Pharmaceutical / Industry
Protocol IDs: ASI-HDIII 0109, NCT00816959
Three Different Therapy Regimens in Treating Patients With Previously Untreated Hodgkin Lymphoma
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: CDR0000633503, GOELAMS-LH2007, GOELAMS-ID-RCB#2007-A01079-44, INCA-RECF0754, AMGEN-GOELAMS-LH2007, NCT00920153
HD17 for Intermediate Stage Hodgkin Lymphoma
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 60
Sponsor: Other
Protocol IDs: HD17, NCT01356680
A Study of Trabectedin (YONDELIS) in Patients With Locally Advanced or Metastatic Liposarcoma or Leiomyosarcoma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 15 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CR017269, ET743SAR3006, NCT01692678
Phase 3 Frontline Therapy Trial in Patients With Advanced Classical Hodgkin Lymphoma
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: C25003, 2011-005450-60, U1111-1161-4937, 12/LO/1950, JapicCTI-142491, NCT01712490
Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CMEK162A2301, 2012-003593-51, NCT01763164
PV-10 Intralesional Injection vs Systemic Chemotherapy for Treatment of Locally Advanced Cutaneous Melanoma
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: PV-10-MM-31, NCT02288897
Phase I and Consecutive Phase II, Two-arm, Randomized Multi-center Trial in Patients With Advanced Melanoma
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: MEL001, NCT01614301
Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin Lymphoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2013-00046, 085, PAMC-085_A05PAMDREVW01, 2014-003678-18, AMC-085, U01CA121947, NCT01771107
A Phase I/II Dose Escalation Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Dacarbazine for Patients With Metastatic Melanoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 70
Sponsor: Pharmaceutical / Industry
Protocol IDs: PH-L19IL2DTIC-04-12, NCT02076646
Adjuvant, Combined Interleukin 2 (Proleukin) and DTIC (Dacarbazine) in High-risk Melanoma Patients
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 07.0008, NCT00553618
Positron Emission Tomography (PET)-Adapted Chemotherapy In Advanced Hodgkin Lymphoma (HL)
Phase: Phase II
Type: Diagnostic, Treatment
Status: Active
Age: 18 to 60
Sponsor: Other
Protocol IDs: GITIL - HD0607, NCT00795613
Study Comparing R-mabHD and a Combination of ABVD in Hodgkin's Disease
Phase: Phase II
Type: Treatment
Status: Approved-not yet active
Age: 18 to 65
Sponsor: Pharmaceutical / Industry
Protocol IDs: ASI-HDII 1108, NCT00797472
Safety Study of Combined Chemotherapy and Endostar to Untreated Patients With Advanced Melanoma
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: simcere001, simcere0801, NCT00813449
SentoClone® Compared to Reference Treatment in Advanced Malignant Melanoma
Phase: Phase II
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: Mel-Swe-01 2009-12-17, EudraCT No: 2008-007515-33, NCT00991250
Response-Based Therapy Assessed By PET Scan in Treating Patients With Bulky Stage I and Stage II Classical Hodgkin Lymphoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Diagnostic, Treatment
Status: Active
Age: 18 to 60
Sponsor: NCI, Other
Protocol IDs: CALGB-50801, CDR0000669076, NCI-2011-02034, NCT01118026
Chemotherapy Based on Positron Emission Tomography Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Diagnostic, Treatment
Status: Active
Age: 18 to 60
Sponsor: NCI, Other
Protocol IDs: CDR0000672913, CALGB-50604, NCT01132807
Anti-CD20 (Cluster of Differentiation Antigen 20) Therapy to Treat Metastatic Melanoma
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: EudraCT: 2010-023277-19, NCT01376713
Start Over